GLOBUS MED INC A (GMED) is drawing unusual attention today. Our newswire has captured 1 story on GMED across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 34/100).
Globus Medical Inc. A (GMED) fell 4.92% to $76.93 on Monday, marking a sharp decline in early trading. The move came ahead of the company's scheduled second-quarter earnings release and conference call set for July 30, 2026. The stock opened at $81.05 but quickly fell to a session low of $76.75 before settling near $76.96. The drop occurred amid mixed analyst coverage and recent insider selling activity.
Globus Medical announced that its second-quarter earnings will be released ahead of market open on July 30, 2026, with a conference call scheduled for 4:30 p.m. ET. The company will provide results for the period ending June 30, 2026. Investors can access the webcast and audio archive online. The announcement coincided with a broader market rally driven by AI chip developments, but GMED faced pressure from recent analyst actions and internal selling. Truist Securities and RBC Capital both cut price targets, while Stifel lowered its target to $80 and maintained a Hold rating. BMO Capital initiated coverage with an Outperform rating and a $94 price target. Meanwhile, Davidar David D, a director, sold shares on June 5, 2026, and total insider sales over the past 90 days reached $2.0 million.
The stock’s intraday move reflected early weakness, with volume reaching 0.7 million shares, or 0.5 times the 3-month average. GMED has a market cap of $10.3 billion and a P/E ratio of 18.9. Revenue has grown 23.5% in the trailing twelve months, with a net margin of 18.9%. The stock has traded between $51.79 and $101.40 over the past 52 weeks. The recent pullback has brought the stock closer to the lower end of its 52-week range, raising questions about earnings expectations and analyst sentiment.
Investors will turn to the July 30 earnings report and conference call for clarity on the company’s performance. The coverage landscape remains mixed, with some analysts lowering price targets and others maintaining bullish stances. The market will also watch for further insider activity and how the stock reacts to earnings.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
NEW YORK, July 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Globus Medical, Inc. (NYSE: GMED) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing....
GLOBUS MED INC A (GMED) is drawing unusual attention today. Our newswire has captured 1 story on GMED across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 34/100). The most recent driver: "Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm" (PR Newswire).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of GMED coverage reads 34/100 over 1 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on GMED: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier GMED move explainers: 2026-07-17